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Abstract
Focal nodular hyperplasia (FNH) is a benign condition of the liver that is often discovered incidentally on radiological
investigation. FNH has no malignant potential, is rarely symptomatic and surgical intervention is almost never required.
However, eight patients with a diagnosis of FNH associated with upper abdominal pain or rapid growth were referred for
surgery. All patients had been extensively investigated for other causes of pain and had been observed for between 1 and 7 years
prior to surgical referral. The FNH lesions were between 1 cm and 8 cm in diameter. One FNH lesion 7.5 cm in diameter lay
in segment VII/VIII and was related to the right and middle hepatic veins. All patients were resected with immediate and
lasting control of their symptoms. Based on this experience FNH should be managed in a manner similar to haemangiomas
with most lesions being safe to observe. However, it should be recognized that symptomatic FNH does occur, as well as FNH
behaving in an unusual fashion such as rapid growth. Both of these findings are indications for resection.
Introduction
Focal nodular hyperplasia (FNH) lesions are benign
liver lesions characterized by the presence of a vascular
red-brown or tan mass with nodules of benign hepatic
parenchyma laced with fibrous septa that may extend
out from a broad central stellate scar [1,2]. FNH is
more common in premenopausal women, although up
to 10% may occur in males [3,4]. The lesions are often
detected incidentally during imaging for non-specific
symptoms of the abdomen and, once the diagnosis has
been established, active treatment is almost never
required [1]. We present a small series of eight patients
with proven FNH who were referred for surgery for
relief of symptoms or because of rapid growth. Hepatic
resection was undertaken in all patients with excellent
outcome.
Methods
A prospective computerized database of patients
managed by the Upper Gastrointestinal/Hepatobiliary
Unit at Auckland Hospital was established in the year
2000 for the purposes of audit after consultation with
the Northern Regional Ethics Committee in Auckland,
New Zealand. Demographic, clinical, pathological,
management and follow-up data are recorded pro-
spectively on all patients managed by the unit. Retro-
spective review of the database identified eight patients
with a proven diagnosis of FNH of the liver who had
undergone resection of the lesion for relief of symptoms
or documented rapid increase in size. All patients were
then followed up prospectively to assess the effective-
ness of resection for control of symptoms.
Results
Demographics
All patients with FNH were Caucasian females with a
median age of 37 years (range 16–52 years). The
presenting symptom in seven of them was abdominal
pain present for a median of 2 years (range 1–7 years).
Apart from patient no. 8 the pain was uniformly
described as a constant dull ache in the right upper
quadrant without exacerbating or relieving factors
(Table I). Patient no. 8 experienced pain only on
running or jogging, with pain increasing in severity with
the duration of exercise. Patient no. 4 was referred
because of a rapidly enlarging lesion noted incidentally
on ultrasound carried out to investigate mildly ab-
normal liver function tests. Subsequently a contrast-
enhanced CT scan was obtained (Figure 1). This
patient was also taking immunosuppressive therapy
following a successful kidney/pancreas transplant for
diabetes mellitus. None of the patients had symptoms
of jaundice or hepatic failure. Of the eight patients,
patient no. 2 was taking a combined oral contraceptive
and patient no. 6 was taking hormone replacement
therapy for menopause-related symptoms (Table I).
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Investigations
All patients were initially investigated with ultrasound
as part of the work-up for upper abdominal pain.
Subsequently all patients were investigated with CT
scan of the liver and three patients also were examined
by MRI (Table II). In all cases the ultrasound, CT and
MRI appearances of the lesions showed hypervascular
soft tissue masses consistent with a diagnosis of FNH.
However patient no. 4 did not have an obvious central
scar and, because of the rapid growth and aggressive
appearance of this lesion, biopsy was undertaken. This
demonstrated only blood and a definitive diagnosis
of FNH was not established preoperatively in this
patient. In addition to investigations specific for the
liver lesions, all patients had undergone a variety of
tests to exclude other causes of right upper quadrant
pain (most commonly gastroduodenoscopy, colono-
scopy and biliary HIDA scan).
The size of the lesions varied between 1 cm in
diameter (patient no. 7) and nearly 8 cm in diameter
(patient no. 5). Most lesions were situated peripherally
in the liver, although patient no. 8 had a large FNH
lesion that lay in an intrahepatic position related to the
right and middle hepatic veins (Figure 2).
Treatment
All patients were referred for hepatic resection follow-
ing extended periods of observation. The duration of
observation ranged from 1 to 7 years. None of the
patients experienced any relief of symptoms or
Table I. Demographic details of eight patients with FNH
Patient
no.
Age
(years) Sex Symptoms
Duration
(years)
Hormone
therapy
1 45 F RUQ pain 1 Nil
2 23 F RUQ pain 1 Oral
contraceptive
3 38 F RUQ pain 3 Nil
4 36 F Incidental,
" size
— Nil
5 27 F RUQ pain 7 Nil
6 52 F RUQ and
flank pain
2 Hormone
replacement
therapy
7 43 F RUQ pain 1.5 Nil
8 16 F RUQ pain 4 Nil
RUQ, right upper quadrant.
Figure 1. (A) Arterial phase CT scan from patient no. 4 following kidney/pancreas transplant showing no abnormality. (B) Arterial phase CT
scan from patient no. 4 taken 18 months after scan A demonstrating a hypervascular mass (arrow) in the right lobe of the liver.
Table II. Details of investigations in eight patients with FNH
Patient
no. US scan CT scan MRI Biopsy Size of FNH (cm) Segment
1 N Y N N 7r6 II/III
2 Y Y Y Y 5.5r4r5 V
3 Y Y N N 1.4r0.5r1 IV/V
4 Y Y Y Y 6r6 VII/VII
5 Y Y N N 8r8 II/III
6 N Y Y Y 4r4 VII
7 Y Y N N 1r2 IVB
8 N Y N N 7.5r6.5r5.5 VII/VIII
US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging.
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shrinkage of the lesions on surveillance scans during
observation. All patients were taking regular oral medi-
cations for pain (including opiates) preoperatively.
After preoperative review surgical resection was
undertaken in all cases (Table III). Following resection
patient nos 1, 3 and 5–8 who had presented with
a long history of pain had relief of their symptoms.
These patients were followed up at 6 weeks, 3 months
and 6 months after resection with no recurrence of
their presenting symptoms and without the need to
recommence regular analgesia (median follow-up
2.0 years, range 1–4 years). Postoperative histology
showed FNH of the traditional type containing
abnormal nodular architecture, abnormal vessels and
cholangiolar proliferation in all cases. All resected
FNH also contained a typical central scar histologi-
cally.
Discussion
Focal nodular hyperplasia comprises benign tumour-
like lesions that are the result of a hyperplastic rather
Figure 2. Contrast-enhanced CT scan from patient no. 8 demonstrating a biopsy-proven FNH lesion (arrow) closely related to the origins of
the right and middle hepatic veins. This patient complained of pain beginning shortly after exercising.
Table III. Details of treatment in eight patients with FNH
Patient
number Procedure
Blood
loss (ml) Complication
Hospital
stay (days)
Symptom
relief
1 Segment 2/3 resection 200 Nil 7 Yes
2 Segment 5 resection 200 Wound sinus 7 Yes
3 Segment 5/6 resection 300 Mild pancreatitis 7 Yes
4 Right lobectomy 400 Wound collection 6 Yes
5 Segment 2/3 resection 300 Nil 5 Yes
6 Segment 4 resection 400 Nil 9 Yes
7 Segment 4 resection 50 Nil 4 Yes
8 Right lobectomy 800 Pneumonia 10 Yes
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than a neoplastic process. They are classically
described as containing thickened plates of hepatic
parenchyma surrounding a central fibrous scar con-
taining malformed vascular structures with radiating
fibrous septa [2]. The pathogenesis of FNH is unclear;
however, Wanless et al. [5] have suggested that FNH
develops as hyperplastic nodules caused by blood
flow in an anomalous hepatic artery branch. Kondo
[6] has also proposed that FNH lesions are a result of
regional abnormalities in either portal or hepatic
arterial blood flow. Certainly FNH lesions are char-
acterized macroscopically by the presence of abnormal,
dilated capsular blood vessels [2], they are known
to occur simultaneously with other vascular hepatic
lesions such as haemangiomas and adenomas [7], and
their incidence may be increased following blunt
abdominal trauma [8] and chemotherapy [9], both
of which are associated with intrahepatic vascular
damage. In addition, an Italian case control study
found that cigarette smoking was an indicator of
elevated risk of FNH [10].
The mechanisms by which FNH lesions may cause
pain are unclear. Malignant change has never been
reported in FNH [2], although FNH may occur in
association with hepatocellular carcinoma [11] and
other tumours [9]. However, there are well documen-
ted cases of intra-lesional haemorrhage [2] and rupture
[12]. As the lesions are intensely vascular and all of the
FNH lesions in this series were related to the liver
capsule it is possible that variations in blood flow
caused pain because of capsular distension. In addi-
tion, patient no. 8 had an FNH lesion that was closely
related to the right and middle hepatic veins and
may have caused pain by restricting hepatic venous
outflow, particularly during exercise. Other investiga-
tors have also noted this phenomenon [13]. Interest-
ingly, in a large study of over 300 FNH cases, Nguyen
et al. [2] found that traditional FNH lesions (i.e. those
containing abnormal nodular architecture, malformed
appearing vessels and cholangiolar proliferation) were
most likely to be associated with symptoms. Other
histological types such as telangiectatic, mixed and
atypical forms were less likely to be associated with
symptoms.
Painful, symptomatic FNH lesions or FNH behav-
ing in an unusual manner are rare. The eight cases
reported in this small series represent a very small
fraction of the total numbers of FNH seen by our unit
and constitute only a very small percentage of the total
numbers of FNH present in the community, although
the exact denominator is unknown. We currently only
record data on patients who undergo resections in our
unit. However, many more patients are seen and
assessed with asymptomatic FNH and discharged from
follow-up. The discovery of an FNH is almost always
an incidental finding. However, the purpose of
presenting these eight patients is to draw attention to
the fact that, while most FNH lesions do not require
intervention, a small minority are associated with
disabling symptoms or abnormal behaviour and
should be considered for surgical resection. In most
of our cases the diagnosis of FNH was not in doubt
and only in patient no. 4 was resection undertaken
to differentiate between FNH and other nodular
hepatic lesions such as adenoma or fibrolamellar
carcinoma. Currently, investigations such as triple-
phase CT scan, magnetic resonance scanning and
careful use of ultrasound-guided core biopsy permit
most patients with FNH to be accurately diagnosed
[3,14].
The use of biopsy in the diagnosis of hypervascular
hepatic lesions is controversial. We believe that the role
of biopsy is to confirm benign pathology in patients
with radiologically benign appearing lesions [15,16].
In the current series biopsy was utilized to confirm
the presence of FNH and to exclude the presence of a
fibrolamellar carcinoma. For the majority of patients
with FNA a benign biopsy result meant that they could
be reassured regarding the absence of cancer, and
safely observed.
Based on our experience FNH should be managed
in a manner similar to hepatic haemangiomas. Once
diagnosed, most lesions do not require treatment or
even regular follow-up. However, lesions should be
resected if they are clearly symptomatic, are behaving
in an abnormal fashion by increasing in size or if
radiological investigations show signs of intra-lesional
haemorrhage.
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